Aspen and Bioiberica have a long-standing partnership: The companies previously collaborated to produce Motilex, a powdered food supplement containing b-2Cool, a native type II collagen. Mobilee combines a high concentration of hyaluronic acid with polysaccharides and collagen, and it was authorized as a novel food ingredient in Brazil in early 2020.
“Brazil is a priority market for both Apsen and Bioiberica, where Motilex, containing b-2Cool, is currently the market leader,” said Kleber Vargas, VP of New Business at Apsen. “The mobility market continues to evolve rapidly in the region and it’s for this reason that we choose to partner with organizations, like Bioiberica, which can support us in the development of cutting-edge solutions with market standout through the provision of high-quality, science-backed ingredients.”
The launch of Motilex HA follows recent scientific research published in Osteoarthritis and Cartilage, which highlights the benefits of combining Bioiberica’s native (undenatured) type II collagen, b-2Cool, with other key ingredients for joint health, including chondroitin sulphate, glucosamine hydrochloride and Mobilee.
“Following the successful development of Motilex, we recognized an opportunity in the market to leverage our combined technical and market expertise and respond to the growing trend for holistic mobility solutions,” said Jaume Reguant, Healthcare Director at Bioiberica
“Rather than focusing on joints and muscles in isolation, we’ve worked closely with Apsen to expand its range and create a new product which uses a powerful combination of hyaluronic acid, polysaccharides, and collagen in the form of Mobilee, alongside native type II collagen to provide health-conscious consumers with an effective solution that supports overall mobility and enables them to achieve their health goals.”